Clinical Trials
14 trialsNCT06014762 2026-05-07
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05020678 2026-04-20
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
Phase 1 Active not recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT07121946 2026-02-10
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
Phase 1 Recruiting
NCT05526313 2025-10-01
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1 Completed
NCT06830031 2025-06-13
C402
Shanghai Exuma Biotechnology Ltd.
Phase 1 Recruiting
NCT04052061 2025-02-21
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Phase 1 Withdrawn
NCT04231747 2024-05-20
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT05487651 2023-05-18
ANCHOR2
Athenex, Inc.
Phase 1 Unknown
NCT01748721 2016-01-08
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
Phase 1 Completed
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00004212 2012-05-16
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
Phase 1 Completed
NCT00077493 2007-12-28
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Suspended